fbpx

News

Lundbeckfonden Ventures News

BONESUPPORT and Orthocell agreement to facilitate:Partnership to co-develop bone repair products utilizing the unique eluting bone remodelling capabilities of CERAMENTT and the important collagen properties of CelgroTOrthocell and BONESUPPORT to co-develop CelgroT collagen scaffold to create next generation bone repair product that also induces bone growth
CANTERBURY, UK, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the addition of Mike Grey to its Board of Directors as an independent director. Mr. Grey is Chairman and Chief Executive Officer (CEO) of Reneo Pharmaceuticals, a privately held biotechnology company, and a Venture...
LEXINGTON, Mass., December 2, 2014 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Leonard D. Schaeffer has been appointed to scPharmaceutical's board of directors.
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases
SAN DIEGO, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to present three-year long-term follow up data of MYDICAR in patients with advanced heart failure during the...
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
Proceeds to enable clinical Phase 2 Proof-of-Concept studies for two lead compounds - a histamine H4 receptor antagonist for atopic dermatitis and a topical cPLA2 inhibitor for psoriasis
Nexstim Plc (Nexstim” or the “Company”) published its initial public offering (the “Offering”) on 13 October 2014, in which the Company offered for subscription up to 2,873,563 new shares. The Company also announced that it will apply for listing of its shares on Nasdaq First North Finland and Nasdaq First North Sweden. The submission of...
Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR®Lonza to initiate design of a new commercial viral therapeutics facility in Portsmouth, NH (USA)         Celladon obtains option to trigger construction of facility and commit to long-term commercial supplyLonza to purchase $10 million of Celladon common stock upon Celladon's decision to trigger construction...
1 44 45 46 47 48 65

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. May 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
7. May 2020
Acacia Pharma Group PLC – Alessandro Della Chà appointed as Director of Acacia Pharma Group plc
9. April 2020